Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
Mult Scler
; 26(10): 1261-1264, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-696957
ABSTRACT
Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
B-Lymphocytes
/
Killer Cells, Natural
/
CD4-Positive T-Lymphocytes
/
Coronavirus Infections
/
Multiple Sclerosis, Chronic Progressive
/
Rituximab
/
Immunity, Cellular
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Mult Scler
Journal subject:
Neurology
Year:
2020
Document Type:
Article
Affiliation country:
1352458520943791
Similar
MEDLINE
...
LILACS
LIS